Binding of the Fap2 protein of fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack

Immunity

Volumn 42, Issue 2, 2015, Pages 344-355

  Gur, Chamutal ^a,b   Ibrahim, Yara ^c   Isaacson, Batya ^a   Yamin, Rachel ^a   Abed, Jawad ^c   Gamliel, Moriya ^a   Enk, Jonatan ^a   Bar On, Yotam ^a   Stanietsky Kaynan, Noah ^a   Coppenhagen Glazer, Shunit ^c   Shussman, Noam ^b   Almogy, Gideon ^b   Cuapio, Angelica ^d   Hofer, Erhard ^d   Mevorach, Dror ^b   Tabib, Adi ^b   Ortenberg, Rona ^e   Markel, Gal ^e   Miklić, Karmela ^f   Jonjic, Stipan ^f   Brennan, Caitlin A ^g   Garrett, Wendy S ^g,h   Bachrach, Gilad ^c   Mandelboim, Ofer ^a   more..

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e SHEBA MEDICAL CENTER   (Israel)

^f UNIVERSITY OF RIJEKA   (Croatia)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BINDING PROTEIN; FAP2 PROTEIN; RECEPTOR; TIGIT RECEPTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; OUTER MEMBRANE PROTEIN; PROTEIN BINDING; TIGIT PROTEIN, HUMAN;

ADENOCARCINOMA CELL LINE; ANIMAL CELL; ARTICLE; BACTERIAL STRAIN; BACTERIUM MUTANT; CELL KILLING; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FUSOBACTERIUM NUCLEATUM; HEMAGGLUTINATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; MICROBIAL ADHESION; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; TRANSPOSON; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; WILD TYPE; ADENOCARCINOMA; ANIMAL; CELL LINE; CELL PROLIFERATION; COLON TUMOR; IMMUNOLOGY; MICROBIOLOGY; NATURAL KILLER CELL; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CELL LINE; CELL PROLIFERATION; COLONIC NEOPLASMS; FUSOBACTERIUM NUCLEATUM; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; PROTEIN BINDING; RECEPTORS, IMMUNOLOGIC; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84923053706     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.01.010     Document Type: Article

References (32)

1. Besser M.J., Shapira-Frommer R., Itzhaki O., Treves A.J., Zippel D.B., Levy D., Kubi A., Shoshani N., Zikich D., Ohayon Y., et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clinical cancer research: an official journal of the American Association for Cancer Research 2013, 19:4792-4800.
2. Castellarin M., Warren R.L., Freeman J.D., Dreolini L., Krzywinski M., Strauss J., Barnes R., Watson P., Allen-Vercoe E., Moore R.A., Holt R.A. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012, 22:299-306.
3. Chaushu S., Wilensky A., Gur C., Shapira L., Elboim M., Halftek G., Polak D., Achdout H., Bachrach G., Mandelboim O. Direct recognition of Fusobacterium nucleatum by the NK cell natural cytotoxicity receptor NKp46 aggravates periodontal disease. PLoS Pathog. 2012, 8:e1002601.
4. Coley W.B. The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc. R. Soc. Med. 1910, 3(Surg Sect):1-48.
5. Coppenhagen-Glazer S., Sol A., Abed J., Naor R., Zhang X., Han Y.W., Bachrach G. Fap2 of Fusobacterium nucleatum is a galactose inhibitable adhesin, involved in coaggregation, cell adhesion and preterm birth. Infect. Immun. 2015, Published online January 5, 2015. 10.1128/IAI.02838-14.
6. Elias S., Yamin R., Golomb L., Tsukerman P., Stanietsky-Kaynan N., Ben-Yehuda D., Mandelboim O. Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood 2014, 123:1535-1543.
7. Gardiner C.M. Killer cell immunoglobulin-like receptors on NK cells: the how, where and why. Int. J. Immunogenet. 2008, 35:1-8.
8. Gonen-Gross T., Goldman-Wohl D., Huppertz B., Lankry D., Greenfield C., Natanson-Yaron S., Hamani Y., Gilad R., Yagel S., Mandelboim O. Inhibitory NK receptor recognition of HLA-G: regulation by contact residues and by cell specific expression at the fetal-maternal interface. PLoS ONE 2010, 5:e8941.
9. Grange J.M., Bottasso O., Stanford C.A., Stanford J.L. The useof mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 2008, 26:4984-4990.
10. Han Y.W., Wang X. Mobile microbiome: oral bacteria in extra-oral infections and inflammation. J.Dent. Res. 2013, 92:485-491.
11. Han Y.W., Redline R.W., Li M., Yin L., Hill G.B., McCormick T.S. Fusobacterium nucleatum induces premature and term stillbirths in pregnant mice: implication of oral bacteria in preterm birth. Infect. Immun. 2004, 72:2272-2279.
12. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
13. Jobin C. Colorectal cancer: looking for answers in the microbiota. Cancer discovery 2013, 3:384-387.
14. Koch J., Steinle A., Watzl C., Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013, 34:182-191.
15. Kostic A.D., Gevers D., Pedamallu C.S., Michaud M., Duke F., Earl A.M., Ojesina A.I., Jung J., Bass A.J., Tabernero J., et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012, 22:292-298.
16. Kostic A.D., Chun E., Robertson L., Glickman J.N., Gallini C.A., Michaud M., Clancy T.E., Chung D.C., Lochhead P., Hold G.L., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013, 14:207-215.
17. Lankry D., Gazit R., Mandelboim O. Methods to identify and characterize different NK cell receptors and their ligands. Methods Mol. Biol. 2010, 612:249-273.
18. Lee P., Tan K.S. Fusobacterium nucleatum activates the immune response through retinoic acid-inducible gene I. J.Dent. Res. 2014, 93:162-168.
19. Liu H., Redline R.W., Han Y.W. Fusobacterium nucleatum induces fetal death in mice via stimulation of TLR4-mediated placental inflammatory response. J.Immunol. 2007, 179:2501-2508.
20. Liu S., Zhang H., Li M., Hu D., Li C., Ge B., Jin B., Fan Z. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 2013, 20:456-464.
21. Rubinstein M.R., Wang X., Liu W., Hao Y., Cai G., Han Y.W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013, 14:195-206.
22. Sears C.L., Garrett W.S. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014, 15:317-328.
23. Seidel E., Glasner A., Mandelboim O. Virus-mediated inhibition of natural cytotoxicity receptor recognition. Cellular and molecular life sciences. Cell. Mol. Life Sci. 2012, 69:3911-3920.
24. Sobhani I., Tap J., Roudot-Thoraval F., Roperch J.P., Letulle S., Langella P., Corthier G., Tran Van Nhieu J., Furet J.P. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE 2011, 6:e16393.
25. Stanietsky N., Simic H., Arapovic J., Toporik A., Levy O., Novik A., Levine Z., Beiman M., Dassa L., Achdout H., et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc. Natl. Acad. Sci. USA 2009, 106:17858-17863.
26. Stanietsky N., Rovis T.L., Glasner A., Seidel E., Tsukerman P., Yamin R., Enk J., Jonjic S., Mandelboim O. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur. J. Immunol. 2013, 43:2138-2150.
27. Strauss J., Kaplan G.G., Beck P.L., Rioux K., Panaccione R., Devinney R., Lynch T., Allen-Vercoe E. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm. Bowel Dis. 2011, 17:1971-1978.
28. Tannock G.W. The search for disease-associated compositional shifts in bowel bacterial communities of humans. Trends Microbiol. 2008, 16:488-495.
29. Témoin S., Chakaki A., Askari A., El-Halaby A., Fitzgerald S., Marcus R.E., Han Y.W., Bissada N.F. Identification of oral bacterial DNA insynovial fluid of patients with arthritis with native and failed prosthetic joints. J.Clin. Rheumatol. 2012, 18:117-121.
30. Verbovetski I., Bychkov H., Trahtemberg U., Shapira I., Hareuveni M., Ben-Tal O., Kutikov I., Gill O., Mevorach D. Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 7. J.Exp. Med. 2002, 196:1553-1561.
31. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., Yokoyama W.M., Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
32. Xu M., Yamada M., Li M., Liu H., Chen S.G., Han Y.W. FadA from Fusobacterium nucleatum utilizes both secreted and nonsecreted forms for functional oligomerization for attachment and invasion of host cells. J.Biol. Chem. 2007, 282:25000-25009.